| ID Source | ID |
|---|---|
| PubMed CID | 157294 |
| CHEBI ID | 187576 |
| MeSH ID | M0141231 |
| Synonym |
|---|
| 6-hydroxyindoramin |
| CHEBI:187576 |
| 79146-88-6 |
| n-[1-[2-(6-hydroxy-1h-indol-3-yl)ethyl]piperidin-4-yl]benzamide |
| benzamide, n-(1-(2-(6-hydroxy-1h-indol-3-yl)ethyl)-4-piperidinyl)- |
| DTXSID40229556 |
| 6-hydroxyindoramin hydrochloride |
| 6-hydroxy indoramin |
| Excerpt | Reference | Relevance |
|---|---|---|
| " No significant differences were observed between values determined under pregnant and post-partum conditions, for any pharmacokinetic parameter." | ( The pharmacokinetics of oral indoramin during pregnancy. Odendaal, HJ; Pierce, DM; Schabort, I, 1990) | 0.28 |
| " Terminal disposition half-life is prolonged after intravenous as well as acute and chronic oral dosing (9." | ( Pharmacokinetics of indoramin and its metabolite 6-hydroxyindoramin after single and multiple doses to cirrhotic liver patients. Giesing, M; Neumann, G; Pierce, DM; Reimold, WV; Wilke, G, 1986) | 0.53 |
| " Inter-subject variation represented the main source of variability in indoramin plasma concentrations with, for example, the between-subjects sum of squares (a measure of the contribution to the total variability) representing around 97% of the total sum of squares for Cmax and AUC (0-24)." | ( Intra- and inter-subject variation in the pharmacokinetics of indoramin and its 6-hydroxylated metabolite. Abrams, SM; Franklin, RA; Pierce, DM, 1988) | 0.27 |
| " In PM subjects, mean values of Cmax (158 ng/ml) and AUC(0-24) (2556 ng X h X m-1) for indoramin were substantially elevated and t 1/2 beta (18." | ( The pharmacokinetics of indoramin and 6-hydroxyindoramin in poor and extensive hydroxylators of debrisoquine. Franklin, RA; Pierce, DM; Smith, SE, 1987) | 0.54 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Bioavailability is increased with a wide range of distribution from 12." | ( Pharmacokinetics of indoramin and its metabolite 6-hydroxyindoramin after single and multiple doses to cirrhotic liver patients. Giesing, M; Neumann, G; Pierce, DM; Reimold, WV; Wilke, G, 1986) | 0.53 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " the same order of magnitude as intra-subject variation seen in volunteers dosed repeatedly with indoramin." | ( The pharmacokinetics of oral indoramin during pregnancy. Odendaal, HJ; Pierce, DM; Schabort, I, 1990) | 0.28 |
| "Pharmacokinetic data obtained after intravenous and single and repeat chronic oral dosing of indoramin in nine patients with liver cirrhosis are described." | ( Pharmacokinetics of indoramin and its metabolite 6-hydroxyindoramin after single and multiple doses to cirrhotic liver patients. Giesing, M; Neumann, G; Pierce, DM; Reimold, WV; Wilke, G, 1986) | 0.53 |
| "The pharmacokinetics of indoramin and its active 6-hydroxylated metabolite have been studied in healthy male volunteers after repeated oral dosing with 37." | ( Pharmacokinetics of indoramin and its 6-hydroxylated metabolite after repeated oral dosing. Franklin, RA; Pierce, DM; Warrington, SJ, ) | 0.13 |
| " The results imply that the kinetic behaviour of indoramin within an individual will prove relatively consistent, despite widespread inter-subject variation, once an appropriate dosage regime has been established." | ( Intra- and inter-subject variation in the pharmacokinetics of indoramin and its 6-hydroxylated metabolite. Abrams, SM; Franklin, RA; Pierce, DM, 1988) | 0.27 |
| " Plasma concentrations of an active metabolite, 6-hydroxyindoramin, after single oral doses in either dosage form, were of a similar order to those of unchanged drug and fell with similar rapidity." | ( Pharmacokinetics and systemic availability of the antihypertensive agent indoramin and its metabolite 6-hydroxyindoramin in healthy subjects. Abrams, SM; Franklin, RA; Pierce, DM, 1987) | 0.74 |
| Class | Description |
|---|---|
| tryptamines | Tryptamine and its substitution derivatives. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (80.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.36) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||